Atezolizumab and Durvalumab Show Similar Benefit for ES-SCLC

EP: 1.Approaches and Obstacles to Frontline Treatment for Small Cell Lung Cancer

Now Viewing

EP: 2.Atezolizumab and Durvalumab Show Similar Benefit for ES-SCLC

EP: 3.Frontline Targeted Options for EGFR-Mutated NSCLC

EP: 4.Sequencing Osimertinib in Patients With EGFR-Mutated NSCLC

EP: 5.Expert Compares Atezolizumab and Durvalumab as Therapy for ES-SCLC

EP: 6.Approaching Treatment for a Patient With NSCLC and an EGFR Mutation

EP: 7.Overview of Available Therapies for EGFR Mutations in Lung Cancer

EP: 8.Strategies for Managing Adverse Events of Osimertinib for EGFR+ NSCLC

EP: 9.Ways to Manage Toxicities Related to Osimertinib for Lung Cancer

EP: 10.Osimertinib Proves Frontline Status in EGFR+ Advanced NSCLC

EP: 11.Reviewing OPAL Results in EGFR+ NSCLC Before Phase 3 FLAURA2 Presentation

EP: 12.FLAURA Data Provides Insight on Sequencing Therapy for EGFR+ NSCLC

Joshua K. Sabari, MD, medical director of Kimmel Pavilion 12 at NYU Langone Health’s Perlmutter Cancer Center and assistant professor of medicine at NYU Grossman School of Medicine, discusses the trials that showed efficacy for durvalumab (Imfinzi) and atezolizumab (Tencentriq) in patients with extensive-stage small cell lung cancer (ES-SCLC).

The phase 3 CASPIAN trial (NCT03043872) investigated whether durvalumab with or without tremelimumab given alongside carboplatin or cisplatin and etoposide would improve overall survival (OS) and progression-free survival (PFS) in patients with ES-SCLC versus carboplatin or cisplatin and etoposide alone. The phase 3 IMpower133 trial (NCT02763579) investigated the OS and PFS benefit of atezolizumab with carboplatin and etoposide versus carboplatin and etoposide alone.

According to Sabari, the study designs were similar, though in the CASPIAN trial, up to 6 cycles of platinum-based chemotherapy could be used compared with 4 cycles in the IMpower133 trial. The IMpower133 trial also did not allow enrollment of patients who had received prophylactic cranial irradiation (PCI). Both studies did not allow patients with untreated brain metastases due to the high rate of recurrence and death in patients with central nervous system (CNS) involvement.

The studies had similar positive results, with durvalumab showing an objective response rate (ORR) of 68% in the CASPIAN trial, while atezolizumab had an ORR of 60% in the IMpower133 trial. The hazard ratio for death was nearly identical according to Sabari.

Both trials met their primary end point of OS and PFS, leading to approval by the FDA for use in this setting.

TRANSCRIPTION:

0:08 | I think both of these studies were very similar to each other in their design. The major differences here being that the CASPIAN study using durvalumab allowed for 6 cycles of cisplatin [or carboplatin] use. The ORR in the CASPIAN study appeared to be slightly higher at 68% than in the IMpower133 study, [which was] about 60%. And when you look across both of these studies, though, the rate of CNS recurrence and the rate of mortality in patients who had CNS disease upfront was quite high. So both of these studies did not allow any untreated patients with brain metastases, but did allow for patients with treated metastasis.

0:50 | One other thing that you need to consider is in the CASPIAN study, it did allow for PCI, whereas the IMpower133 study did not. Again, that being said, when you look at the hazard ratio of both of these studies, it’s…0.76 [in IMpower133] and 0.75 [in CASPIAN], being very similar. It's really hard to distinguish. I think one thing that will be interesting in the future is looking at the tail of the [Kaplan-Meier] curve. Are there a substantial number of patients alive and doing well on 1 agent versus the other? That might differentiate these 2 combinations, but in 2022, I don't think there's any major difference between the 2 regimens.